Latest Conference Articles

Kathleen Shuey, M.S., RN, SCON, ACNS-BC, listens and guides us in the right direction in caring for our oncology population.

Heather Patenaude, B.S.N., RN, displays the highest level of technical skills necessary to provide compassionate care to her patients.

GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.

Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

Gayle S. Jameson, M.S.N, ACNP-BC, AOCN, is a trailblazer whose expertise and compassion have made a profound impact on oncology care.

Dr. Susan Rux, a respected nursing leader and researcher, empowers teams, mentors future leaders, and advances inclusive clinical research in kidney cancer.

Mary Anderson, B.S.N., RN, OCN, embodies the spirit of an Extraordinary Healer.

I would like to nominate Ashley Tullio, RN, for the Extraordinary Healer Award for Oncology Nursing.

Everyone knows someone who has been affected by cancer.

It is with great pride and admiration that I nominate Diane Hudson, RN, OCN, for the Extraordinary Healer Award for Oncology Nursing.

The nursing profession is home to countless extraordinary.

Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety.

Reflecting upon my relationship with Jill over the past 25 years, I am in awe of all she has accomplished.

Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise she made as a young caregiver.

Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.”

“Don’t aspire to make a living. Let’s aspire to make a difference in the Mandarin/Cantonese-speaking community.”

The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation.

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.